# Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

> **NCT00727831** · PHASE1,PHASE2 · COMPLETED · sponsor: **University College, London** · enrollment: 4 (actual)

## Conditions studied

- Chemotherapeutic Agent Toxicity
- Lymphoma
- Mucositis
- Neurotoxicity

## Interventions

- **DRUG:** glucarpidase
- **DRUG:** leucovorin calcium
- **DRUG:** methotrexate
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** quality-of-life assessment
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00727831
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2014-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00727831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00727831, "Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00727831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*